Amicus Therapeutics (FOLD) : Acuta Capital Partners reduced its stake in Amicus Therapeutics by 53.54% during the most recent quarter end. The investment management company now holds a total of 1,161,545 shares of Amicus Therapeutics which is valued at $8,061,122 after selling 1,338,455 shares in Amicus Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Amicus Therapeutics makes up approximately 3.95% of Acuta Capital Partners’s portfolio.
Other Hedge Funds, Including , Venbio Select Advisor reduced its stake in FOLD by selling 91,507 shares or 2.6% in the most recent quarter. The Hedge Fund company now holds 3,424,104 shares of FOLD which is valued at $23,763,282. Amicus Therapeutics makes up approx 8.44% of Venbio Select Advisor’s portfolio.Janus Capital Management reduced its stake in FOLD by selling 54,142 shares or 0.96% in the most recent quarter. The Hedge Fund company now holds 5,562,366 shares of FOLD which is valued at $38,602,820. Amicus Therapeutics makes up approx 0.03% of Janus Capital Management’s portfolio. Dynamic Technology Lab Private Ltd added FOLD to its portfolio by purchasing 19,842 company shares during the most recent quarter which is valued at $137,703. Amicus Therapeutics makes up approx 0.03% of Dynamic Technology Lab Private Ltd’s portfolio.Frazier Management reduced its stake in FOLD by selling 192,700 shares or 6.6% in the most recent quarter. The Hedge Fund company now holds 2,725,591 shares of FOLD which is valued at $18,915,602. Amicus Therapeutics makes up approx 16.63% of Frazier Management’s portfolio.Convector Capital Management Lp reduced its stake in FOLD by selling 28,400 shares or 12.12% in the most recent quarter. The Hedge Fund company now holds 206,000 shares of FOLD which is valued at $1,442,000. Amicus Therapeutics makes up approx 1.89% of Convector Capital Management Lp’s portfolio.
Amicus Therapeutics (FOLD) witnessed a volatile trading activity on Thursday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $6.68 and reached the intraday high at $6.83. The bulls started the profit booking and pushed the shares to intraday low of $6.54. The trading session was marked by a volume range of 12,76,492 shares exchanging hands. The 52-week high of the shares is $18.4 and the 52-week low is $4.98. The market cap of the company stands at $951 M and there are 14,21,39,450 shares in public circulation.
On the company’s financial health, Amicus Therapeutics reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36.Analysts expectations of $ .17.
Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.